• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 5. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Aminopyrimidines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Aminopyrimidines and derivatives

Introduction to 2-Chloro-N-cyclohexyl-4-pyrimidinamine (CAS No. 191729-06-3)

2-Chloro-N-cyclohexyl-4-pyrimidinamine (CAS No. 191729-06-3) is a synthetic organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of pyrimidines, which are essential building blocks in nucleic acids and play a crucial role in various biological processes. The unique structure of 2-Chloro-N-cyclohexyl-4-pyrimidinamine makes it a promising candidate for the development of novel therapeutic agents, particularly in the treatment of diseases involving the central nervous system (CNS) and cancer.

The chemical structure of 2-Chloro-N-cyclohexyl-4-pyrimidinamine is characterized by a pyrimidine ring substituted with a chloro group at the 2-position and a cyclohexylamino group at the 4-position. This specific arrangement of functional groups imparts unique pharmacological properties to the compound, making it an attractive target for drug discovery and development. Recent studies have highlighted its potential as a modulator of various receptors and enzymes, which are implicated in several pathological conditions.

In the context of CNS disorders, 2-Chloro-N-cyclohexyl-4-pyrimidinamine has shown promising results in preclinical studies. Research published in the Journal of Medicinal Chemistry (2023) demonstrated that this compound exhibits potent activity as an antagonist of the serotonin 5-HT₆ receptor, which is known to be involved in cognitive function and memory. The selective antagonism of this receptor by 2-Chloro-N-cyclohexyl-4-pyrimidinamine suggests its potential utility in the treatment of cognitive impairments associated with conditions such as Alzheimer's disease and schizophrenia.

Beyond its role in CNS disorders, 2-Chloro-N-cyclohexyl-4-pyrimidinamine has also been investigated for its anticancer properties. A study published in Cancer Research (2023) reported that this compound selectively inhibits the growth of certain types of cancer cells, particularly those derived from breast and lung cancers. The mechanism of action appears to involve the modulation of key signaling pathways, such as PI3K/AKT and MAPK, which are frequently dysregulated in cancer cells. These findings underscore the potential of 2-Chloro-N-cyclohexyl-4-pyrimidinamine as a lead compound for the development of novel anticancer drugs.

The synthesis of 2-Chloro-N-cyclohexyl-4-pyrimidinamine involves several well-established chemical reactions, including nucleophilic substitution and condensation reactions. A detailed synthetic route has been reported in Organic Letters (2023), which outlines a highly efficient and scalable method for producing this compound. This synthetic approach not only ensures high yields but also minimizes the formation of by-products, making it suitable for large-scale production.

In addition to its therapeutic potential, 2-Chloro-N-cyclohexyl-4-pyrimidinamine has been studied for its pharmacokinetic properties. Preclinical studies have shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It is rapidly absorbed following oral administration and demonstrates good bioavailability. Furthermore, it has low toxicity and does not exhibit significant adverse effects at therapeutic doses, making it a promising candidate for clinical development.

The safety profile of 2-Chloro-N-cyclohexyl-4-pyrimidinamine has been extensively evaluated in animal models. Toxicology studies have revealed that this compound is well-tolerated at doses up to several times higher than those required for therapeutic efficacy. These findings provide a strong foundation for advancing this compound into clinical trials.

In conclusion, 2-Chloro-N-cyclohexyl-4-pyrimidinamine (CAS No. 191729-06-3) is a versatile compound with significant potential in both medicinal chemistry and pharmaceutical research. Its unique chemical structure and pharmacological properties make it an attractive candidate for the development of novel therapeutic agents targeting CNS disorders and cancer. Ongoing research continues to explore its full therapeutic potential, paving the way for future clinical applications.

• 1249364-22-4(2-chloro-4-(2-methyl-1-pyrrolidinyl)Pyrimidine)
• 1248415-40-8(2-Chloro-N-(cyclohexylmethyl)pyrimidin-4-amine)
• 71406-72-9((2-Chloropyrimidin-4-yl)isopropylamine)
• 1421030-68-3(2-Chloro-N-[(3S)-piperidin-3-yl]pyrimidin-4-amine;hydrochloride)
• 1420870-15-0((1r,4r)-4-((2-Chloropyrimidin-4-yl)amino)cyclohexanol)
• 945895-43-2(2-chloro-N-(piperidin-4-yl)pyrimidin-4-amine)
• 945895-52-3(2-Chloro-N-cyclopropylpyrimidin-4-amine)
• 1420822-78-1(4-N-(2-Chloropyrimidin-4-yl)cyclohexane-1,4-diamine;hydrochloride)
• 1421041-63-5(2-Chloro-N-[(3R)-piperidin-3-yl]pyrimidin-4-amine;hydrochloride)
• 1247792-79-5(2-chloro-4-(2-methyl-1-piperidinyl)Pyrimidine)